CD274 and non-small cell lung carcinoma: Since 2016, five PD-(L)1 inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab, and cemiplimab) have been approved by the FDA as second- and/or first-line treatment options for advanced NSCLC [93].